Contraception
Conditions
Keywords
birth control, continuation, abortion, contraception
Brief summary
This study will assess the continuation rates among women using oral contraceptive pills, Depo-Provera and Ortho Evra following a first trimester abortion.
Detailed description
Unintended pregnancy rates among women in the United States continue to surpass that of the rest of the developed world at great cost to society. Contraceptive failure has been attributed to poor compliance with contraceptive methods and results in unintended pregnancies. This study will evaluate the 3-month continuation rates among women using the oral contraceptive pill and Depo-Provera. It will also assess the continuation rates of Ortho Evra®, which has not previously been studied in the adolescent population. This study will provide information with regard to pregnancy rates and 3-month patterns of use of contraception among women seeking first-trimester abortion. It will also assess other factors contributing to successful contraception such as the use of emergency contraception and concomitant condom use. The results of this study will be used to inform the practice of providers who provide reproductive health care to women and add to the sparse body of literature available comparing the success of different contraceptive methods used by women.
Interventions
None listed
Sponsors
Emory University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
13 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 13-45 women presenting at the ambulatory surgery at Grady Memorial Hospital who want to use either oral contraceptive pills, ortho evra or depo provera?
Exclusion criteria
* Leaving the Atlanta area within 6 months? * Desires pregnancy within the next 6 months? * Unable to provide contact information? * Contraindications to hormonal contraceptive?
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Continuation Rates | 3 months | We followed subjects to evaluate the continuation rates for subjects receiving oral contraceptive pills, Depo Provera and Ortho Evra. |
Countries
United States
Participant flow
Recruitment details
Participants were recruited from a medical clinic beginning in 10/2004 through 11/2005.
Pre-assignment details
All patients were invited to participate.
Participants by arm
| Arm | Count |
|---|---|
| Oral Contraceptive Participants self-selected to receive oral contraceptives. | 111 |
| Depo Provera Participants self-selected to receive Depo Provera | 109 |
| Ortho Evra Participants self-selected to receive Ortho Evra. | 101 |
| Total | 321 |
Baseline characteristics
| Characteristic | Oral Contraceptive | Depo Provera | Ortho Evra | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 111 Participants | 109 Participants | 101 Participants | 321 Participants |
| Sex: Female, Male Female | 111 Participants | 109 Participants | 101 Participants | 321 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| The measure is of what contraceptive method the participants chose to use <=18 years | 0 participants | 0 participants | 0 participants | 0 participants |
| The measure is of what contraceptive method the participants chose to use >=65 years | 0 participants | 0 participants | 0 participants | 0 participants |
| The measure is of what contraceptive method the participants chose to use Between 18 and 65 years | 111 participants | 109 participants | 101 participants | 321 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 111 | 0 / 109 | 0 / 101 |
| serious Total, serious adverse events | 0 / 111 | 0 / 109 | 0 / 101 |
Outcome results
Primary
Continuation Rates
We followed subjects to evaluate the continuation rates for subjects receiving oral contraceptive pills, Depo Provera and Ortho Evra.
Time frame: 3 months
Population: It was a convenience sample.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Oral Contraceptive | Continuation Rates | 82 participants |
| Depo Provera | Continuation Rates | 78 participants |
| Ortho Evra | Continuation Rates | 83 participants |